Subject: NIH GUIDE - V21(05) 02/07/92
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Fri, 07 Feb 92 08:48 EST

Hi,
  Please post to the NIH Listserver as:
     NIHGUIDE.920207
 ---------------------------- Text of forwarded message -----------------------
$$XID NIHGUIDE 19920207 V21N05 P1O1 ************************************
No RFAs present
 
NIH GUIDE - Vol. 21, No. 5 - February 7, 1992
 
$$INDEX BEGIN *******************************************************
 
                               NOTICES
 
$$INDEX N1 **********************************************************
 
"OTHER SUPPORT" IN PHS GRANT APPLICATIONS
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; ALCOHOL, DRUG ABUSE, AND MENTAL
HEALTH ADMINISTRATION
 
$$INDEX N2 **********************************************************
 
"OTHER SUPPORT" IN NIH AND ADAMA R&D CONTRACT PROPOSALS
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; ALCOHOL, DRUG ABUSE, AND MENTAL
HEALTH ADMINISTRATION
 
$$INDEX N3 **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION
 
               NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 **********************************************************
 
MICROSTIMULATION OF THE SACRAL SPINAL CORD - CHRONIC STIMULATION (RFP
NIH-NINDS-92-15)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE
 
                    ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 **********************************************************
 
BIOMEDICAL RESEARCH SUPPORT GRANT (PA-92-38)
National Center for Research Resources
INDEX:  RESEARCH RESOURCES
 
$$INDEX P2 **********************************************************
 
ANTIPHOSPHOLIPID ANTIBODY AND LUPUS ANTICOAGULANT (PA-92-39)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Heart, Lung, and Blood Institute
INDEX:  ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; HEART, LUNG, BLOOD
 
$$INDEX P3 **********************************************************
 
POST-POLIO SYNDROME (PA-92-40)
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE
 
                                ERRATUM
 
$$INDEX E1 **********************************************************
 
MINORITY SCHOOL FACULTY DEVELOPMENT AWARD
National Cancer Institute
INDEX:  CANCER
 
$$INDEX E2 **********************************************************
 
EXPLORATORY CENTERS FOR BIOBEHAVIOR SYMPTOM MANAGEMENT
National Center Nursing Research
INDEX:  NURSING RESEARCH
 
$$INDEX END *********************************************************
 
                                NOTICES
 
$$N1 BEGIN **********************************************************
 
"OTHER SUPPORT" IN PHS GRANT APPLICATIONS
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
P.T. 34; K.W. 1014002, 1014006
 
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
 
The PHS 398 (rev. 10/88) and PHS 2590 (rev. 10/88) grant application
forms include a section on OTHER SUPPORT, where applicants are expected
to list all, including both Federal and non-Federal, active support and
pending and planned requests for support of research and
research-related activities by all key personnel listed for each
application.  This information is important to PHS review-award
processes to help evaluate the compatibility of application requests
with investigators' capabilities and responsibilities, and eliminate
unwarranted duplication of support for investigators' efforts.
Application instructions emphasize the requirement for complete,
accurate, and reliable information.  In signing the face page of the
application the principal investigator/program director and the
applicant institution official certify that the application information
is accurate and complete.
 
Applicants are reminded of the necessity to provide the full and
reliable information requested.  As noted in the instructions,
"Incomplete, inaccurate, or ambiguous information about OTHER SUPPORT
could lead to delays in review of the application." Further, applicants
should be cognizant that serious consequences could result if failure
to provide complete and accurate information be construed as an attempt
to mislead PHS agency advisory groups and staff in their review and
award responsibilities.
 
$$N1 END ************************************************************
 
$$N2 BEGIN **********************************************************
 
"OTHER SUPPORT" IN NIH AND ADAMHA R&D CONTRACT PROPOSALS
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
P.T. 34; K.W. 1014002, 1014006
 
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
 
Documentation required in National Institutes of Health and Alcohol,
Drug Abuse, and Mental Health Administration uniform Request for
Proposals include Standard Form 1411, Contract Pricing Proposal Cover
Sheet, which instructs offerors to identify any contracts or
subcontracts they have been awarded "for the same or similar items"
within the past three years.  Additionally, offerors are required to
provide a Summary of Related Activities, identifying all active federal
contracts, cooperative agreements, grants, and commercial agreements,
and submitted proposals, including actual and proposed levels of effort
for all key individuals in the proposal to NIH.
 
As with PHS grant applications, mentioned just above, offerors should
be aware that serious consequences could result if their failure to
provide complete and accurate information be construed as an attempt to
mislead agency advisory groups and staff in their review and award
responsibilities.
 
$$N2 END ************************************************************
 
$$N3 BEGIN **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
P.T. 42; K.W. 0783005
 
National Institutes of Health
Food and Drug Administration
 
The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are sponsoring a series of workshops on the
responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research.  The workshops are open to everyone with an interest in
research involving human subjects.  The meetings should be of special
interest to those persons currently serving or about to begin serving
as a member of an IRB.  Issues discussed at these workshops are
relevant to all other Public Health Service agencies.  The current
schedule includes the following:
 
SOUTH MIDWESTERN WORKSHOP
 
DATES:  February 20 and 21, 1992
 
WORKSHOP SITE:  San Antonio, TX
 
SPONSORS:
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX  78284-7972
 
St. Mary's University
One Camino Santa Maria
San Antonio, TX  78228-8572
 
REGISTRATION CONTACT:
Ms. Angie Khan
Institutional Coordinator of Research Review
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive (Room 402L)
San Antonio, TX  78284-7972
Telephone:  (512) 567-2351
 
TOPIC:  Identifying and Assessing Risks in Human Subject Research
 
For further information regarding these workshops and future NIH/FDA
National Protection of Human Subjects Workshops, please contact:
 
Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101
 
$$N3 END ************************************************************
 
                    NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN RFP NIH-NINDS-92-15 **************************************
 
MICROSTIMULATION OF THE SACRAL SPINAL CORD - CHRONIC STIMULATION
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
RFP AVAILABLE:  NIH-NINDS-92-15
 
P.T. 34; K.W. 0745047, 0740050, 1002030
 
National Institute of Neurological Disorders and Stroke
 
The Neural Prosthesis Program of the National Institute of Neurological
Disorders and Stroke (NINDS), National Institutes of Health, is seeking
a contractor to develop a method of chronic microstimulation of the
sacral spinal cord and to evaluate its effects on neural and
surrounding tissue in non-human animals.  Information from spinal cord
microstimulation studies is especially needed by designers of neural
prostheses for paraplegic individuals who have sustained injuries to
the spinal cord above the sacral region.  Before microstimulation of
the spinal cord can be evaluated in humans, a suitable chronic
microstimulating electrode must be developed and its safety and
effectiveness demonstrated in animals.  A research team with experience
in electrophysiology, microelectrode fabrication, and histopathological
examination of neural tissue will be required to successfully conduct
this research.  It is anticipated that one award will be made for a
period of three years in September 1992.
 
This is not a Request for Proposals (RFP).  To receive a copy of the
RFP, submit a written request to the following address, and supply this
office with two self-addressed mailing labels.  The RFP will be issued
on or about February 7, 1992, with proposals due on April 6, 1992.  All
responsible sources shall be considered by the agency.
 
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological Disorders and Stroke, NIH
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, MD  20892
 
Attention:  RFP No. NIH-NINDS-92-15
 
$$R1 END ************************************************************
 
                         ONGOING PROGRAM ANNOUNCEMENTS
 
$$P1 BEGIN PA-92-38 *************************************************
 
BIOMEDICAL RESEARCH SUPPORT GRANT
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
PA NUMBER:  PA-92-38
 
P.T. 34; K.W. 0710030, 1014006
 
National Center for Research Resources
 
Application Receipt Date:  June 15, 1992
 
PURPOSE
 
The National Center for Research Resources announces the Biomedical
Research Support Grant (BRSG) Program for Fiscal Year (FY) 1992.
Because the FY 1992 appropriation of $5,204,000 for the BRSG Program is
a significant reduction in the amount of funds available, awards which
will be made on a competitive basis and fewer awards will be made.
 
The objectives of the BRSG Program for FY 1992 have been narrowed to
focus on support for biomedical research projects in ways that are not
adequately or efficiently provided for by other funding mechanisms such
as the traditional investigator-initiated research project grant.
 
The allowable uses of BRSG funds for FY 1992 are:
 
o  Pilot research.  Small, short-term projects that explore new
research ideas (including multidisciplinary collaborations to explore
new directions in biomedical research), seek preliminary findings, and
establish the validity of the approach and pilot data that may provide
the basis for research project grant applications.
 
o  New investigators.  Initial research support for new investigators
and investigators who have recently relocated and are in the process of
applying for longer-term funding.
 
o  Unexpected requirements and opportunities for projects supported by
other NIH funding mechanisms.  This includes funding to enable research
programs to continue during temporary lapses in project grant support.
 
These uses exploit the capacity of the BRSG to respond promptly to
short-term, low-cost needs that are essential to complement research
project grant mechanisms that typically fund continuing, multi-year
programs.
 
ELIGIBILITY REQUIREMENTS
 
Institutions eligible to apply must have received a minimum of three
allowable Public Health Service (PHS) research grants and/or
cooperative agreements, totalling $200,000 (including direct and
indirect costs), awarded by the PHS during FY 1991.  The guidelines
which are available from the office listed under INQUIRIES describes
the types of research grants that are allowable.  The types of
institutions eligible to apply remain unchanged, i.e., Health
profession schools, graduate schools, hospitals, research
organizations, and health departments. [If applicants are not selected
for a BRSG award, they will remain eligible for the Shared
Instrumentation Grant (SIG) and the Minority High School Student
Research Apprentice Program (MHSSRAP).]
 
MECHANISM OF SUPPORT
 
The grant mechanism used for this program will be the S07 grant.
Awards of $50,000 for direct costs will be made for a twelve-month
project period.  No indirect costs will be provided.  Final funding
decisions will depend on the availability of funds.  All awards will be
made on or before September 30, 1992.
 
Because of the delay in the FY 1992 BRSG award process,the NCRR plans
to extend the ending date of all active FY 1991 BRSG awards through
September 29, 1992.  Revised awards reflecting this extension will
reach the institutions prior to the current March 31 end date of the FY
1991 award period
 
RESEARCH OBJECTIVES
 
The BRSG Program complements the support of biomedical and behavioral
research conducted through research project grants.  The program thus
enhances the productivity and cost-effectiveness of potential and
existing PHS research project grants.
 
APPLICATION PROCEDURES
 
Letters of instructions and modified guidelines providing more specific
information are being sent to Program Directors and institutional
officials at institutions that, according to NIH records, received the
required amount of funds from PHS grants in FY 1991.  The narrative
portion of applications will be limited to two to three pages in length
and must address the items raised in the Review Procedures and Award
Criteria sections.  The receipt date for applications is June 15, 1992.
Applications received after that date will be returned to the
applicant.
 
REVIEW PROCEDURES
 
The NIH will conduct an administrative review, which is not intended to
replace or duplicate on-site scientific and technical review of
research application that will take into consideration the following
criteria:
 
o  The role of the institutional BRSG Advisory Committee and the
quality of the local peer review mechanisms in evaluating the
scientific and technical merit of the proposed projects.
 
o  Overall appropriateness and potential of the proposed portfolio to
improve the quality and maximize the benefits, cost effectiveness, and
productivity of planned or ongoing PHS research project grants.
 
o  Accomplishments achieved with BRSG funds over the last three fiscal
years.
 
o  Level of institutional commitment as indicated by matching
contributions toward the proposed FY 1992 BRSG activities.
 
The second level review will be by the National Advisory Research
Resources Council.
 
AWARD CRITERIA
 
Applications will compete for available funds with all other BRSG
applications received for the June receipt date.  Funding decisions
will be based on:
 
o  Merit of the overall plan as determined by administrative review.
 
o  Program balance:  awards will be distributed equally among the top
third, middle third and lower third of institutions ranked on the basis
of the amount of dollars awarded by PHS for research in FY 1991, i.e.,
the "research grants base."
 
o  Availability of funds.
 
INQUIRIES
 
Direct inquiries regarding programmatic issues to:
 
BRS Program Office
Westwood Building, Room 10A11
Bethesda, MD  20892
Telephone:  (301) 496-6743
 
Direct inquiries regarding fiscal matters to:
 
National Center for Research Resource
Office of Grants and Contracts Management
Westwood Building, Room 853
Bethesda, MD  20892
Telephone:  (301) 496-9840
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
Number 93.337, Biomedical Research Support.  Awards will be made under
authorization of the Public Health Service Act, Title III, Part A,
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241) and
administered under PHS grants policies and Federal Regulations 45 CFR
Part 74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency Review.
 
$$P1 END ************************************************************
 
$$P2 BEGIN PA-92-39 *************************************************
 
ANTIPHOSPHOLIPID ANTIBODY AND LUPUS ANTICOAGULANT
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
PA NUMBER:  PA-92-39
 
P.T. 34; K.W. 0715015, 0710070, 0755020, 0765035
 
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Heart, Lung, and Blood Institute
 
PURPOSE
 
The Arthritis Research Program of the National Institute of Arthritis
and Musculoskeletal and Skin Diseases (NIAMS) supports research on the
autoantibodies found in patients with systemic lupus erythematosus.
The Thrombosis and Hemostasis Branch of the National Heart, Lung, and
Blood Institute (NHLBI) supports research on hypercoagulability and
thrombosis.  The NIAMS and the NHLBI, through this program
announcement, encourage the submission of grant applications for basic
and clinical research related to antiphospholipid antibody and the
lupus anticoagulant.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This program
announcement, Biology of Autoimmune Antiphospholipid Antibody and Lupus
Anticoagulant, is related to the priority areas of health promotion:
maternal and infant health and heart disease and stroke.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone
202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by foreign and domestic, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State or local governments,
and eligible agencies of the Federal government.  Applications from
minority individuals and women are encouraged.  Foreign institutions
are not eligible for the K awards.
 
MECHANISM OF SUPPORT
 
Investigators may apply for research project grants (R01), First
Independent Research Support and Transition (FIRST) awards, (R29), and
career development (K04, K08, K11) awards.
 
RESEARCH OBJECTIVES
 
Background
 
Autoimmune antiphospholipid antibody and lupus anticoagulant, two
closely related antibodies, are associated with a clinical syndrome
consisting of recurrent thromboocclusive disease, livedo reticularis,
and repeated in utero fetal deaths.  Many persons with this antibody do
not have systemic lupus erythematosus and some are apparently well.
Among persons with clinical illness attributable to antiphospholipid
antibody, there is considerable heterogeneity of symptoms and of
antibody characteristics.  The mechanisms by which clinical events
occur are unknown.  A serum cofactor, apolipoprotein H, is generally
required for the binding of autoimmune antibody to phospholipid in the
most commonly used solid phase assay, but precise knowledge concerning
the physical nature of the antigen and the relevance of the cofactor in
antibody binding is still lacking.  Animal models for the antibody and
for the syndrome do not currently exist.  Although anticoagulation with
drugs, such as aspirin or warfarin, are frequently used for treatment,
there is as yet no uniform regimen for all clinical conditions
associated with the antibodies and no definitive clinical trials have
yet been conducted.
 
On September 25, 1991, the NIAMS and the NHLBI co-sponsored an
Antiphospholipid Antibody/Lupus Anticoagulant Workshop.  This Workshop
identified research issues that form the basis of this program
announcement.  These issues include:  the nature of the relationship
between antiphospholipid antibody and lupus anticoagulant; the roles of
apolipoprotein H and of other phospholipid binding proteins in antibody
binding and in clinical illness; the chemical or structural nature of
the antigen or epitope; the (presumably) exogenous trigger for
induction and maintenance of antiphospholipid antibody in patients; the
reasons for patient heterogeneity; and the construction of animal
models.  Treatments for the various clinical manifestations of the
syndrome comprise an additional question.
 
Research Goals and Scope
 
The primary goal of this program announcement is to foster research
that enhances knowledge about mechanisms of action of antiphospholipid
antibody.  This goal includes, but is not limited to, studies that
integrate multidisciplinary approaches.
 
The scope of possible research areas includes, but is not limited to,
the following topics:
 
o  Studies of phospholipid structure relevant to antigenicity;
 
o  Studies of the interaction of phospholipid-binding proteins,
including annexins and antiphospholipid antibodies, with phospholipids;
 
o  Studies of the induction and/or maintenance of antiphospholipid
antibody;
 
o  Studies defining the differences and/or similarities between
antiphospholipid antibody and lupus anticoagulant;
 
o  Elucidation of the mechanisms by which lupus anticoagulants and
phospholipid antibodies promote hypercoagulability and thromboembolic
events;
 
o  Studies of the pathophysiology of fetal death associated with
antiphospholipid antibodies;
 
o  Animal models;
 
o  Clinical studies, including differences and/or similarities between
patients with systemic lupus erythematosus and those with primary
antiphospholipid antibody syndrome;
 
o  Treatment trials.
 
Investigators are encouraged to use the full range of current
disciplines and techniques available to them.
 
STUDY POPULATIONS
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements are required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis must be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale must be provided.
 
The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study.  This information must be included in the form PHS 398 in
Section 2, A-D of the Research Plan AND summarized in Section 2, E,
Human Subjects.  Applicants/offerors are urged to assess carefully the
feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).  The rationale
for studies on single minority population groups must be provided.
 
For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.
 
The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.
 
For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.
 
If the required information is not contained within the application,
the review will be deferred until the information is provided.
 
Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.
 
All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.
 
APPLICATION PROCEDURES
 
Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research Resources
may want to identify the GCRC as a resource for conducting the proposed
research.  If so, a letter of agreement from either the GCRC Program
Director or Principal Investigator must be included with the
application.
 
Applications are to be submitted on the grant application form PHS 398
(rev. 10/88) (applications submitted after May 1 are to use the PHS 398
(rev 9/91)) and will be accepted at the standard application deadlines
as indicated in the application kit.
 
Application kits are available at most institutional business offices
and may be obtained from the Office of Grants Inquiries, Division of
Research Grants, Westwood Building, Room 449, National Institutes of
Health, Bethesda, MD 20892, telephone 301/496-7441.  The title and
number of the announcement must be typed in Section 2 on the face page
of the application.
 
The completed original application and six legible copies must be sent
or delivered to:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
 
REVIEW PROCEDURES
 
Applications will be assigned on the basis of established Public Health
Service referral guidelines.  R01 and R29 applications will be reviewed
for scientific and technical merit by study sections of the Division of
Research Grants, NIH.  Initial review of applications for the K series
will be by the review group of the relevant Institute or Center in
accordance with the standard NIH peer review procedures.  Following
scientific/ technical review, the applications will receive a
second-level review by the appropriate national advisory council.
 
AWARD CRITERIA
 
Applications will compete for available funds with all other approved
applications assigned to that ICD.  The following will be considered
making funding decisions:
 
o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the announcement.
 
INQUIRIES
 
Written and telephone inquiries are encouraged.  The opportunity
to clarify any issues or questions from potential applicants is
welcome.
 
Direct inquiries regarding programmatic issues to:
 
Lawrence Petrucelli, Ph.D.
Arthritis Program Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 406
Bethesda, MD  20892
Telephone:  (301) 496-7326
 
or
 
Carol H. Letendre, Ph.D.
Acting Chief, Thrombosis and Hemostasis Branch
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute
Federal Building, Room 516
Bethesda, MD  20892
Telephone:  (301) 496-8966
 
Direct inquiries regarding fiscal matters to:
 
Diane M. Watson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 407-A
Bethesda, MD  20892
Telephone:  (301) 496-7495
 
or
 
Jane R. Davis
Section Chief, Blood Diseases and Resources
National Heart, Lung and Blood Institute
Westwood Building, Room 4A15C
Bethesda, MD  20892
Telephone:  (301) 496-7257
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
Numbers 93.846, Arthritis, Musculoskeletal and Skin Diseases Research
and 93.839, Blood Diseases and Resources Research.  Awards are made
under authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and
285) and administered under PHS grants policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
 
$$P2 END ************************************************************
 
$$P3 BEGIN PA-92-40 *************************************************
 
POST-POLIO SYNDROME
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
PA NUMBER:  PA-92-40
 
P.T. 34; K.W. 0715125, 0785055, 0765035, 0710070, 0755020
 
National Institute of Neurological Disorders and Stroke
 
PURPOSE
 
The National Institute of Neurological Disorders and Stroke (NINDS)
encourages the submission of applications for research grants related
to the post-polio syndrome.  The NINDS invites grant applications to
support research in all aspects of the post-polio syndrome including
epidemiology, diagnosis, pathophysiology, immunology, therapy, and the
development of animal models.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention goals of "Healthy People 2000," a
PHS-led national activity for setting priorities.  This program
announcement, Post-polio Syndrome, is related to the priority area of
diabetes and chronic disabling conditions.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  No.
017-001-00474-0, or Summary Report:  Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office,
Washington, DC  20402-9325 (Telephone:  202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by foreign and domestic, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State or local governments,
and eligible agencies of the Federal government.  Applications from
minority individuals and women are encouraged.
 
MECHANISMS OF SUPPORT
 
Support for this program announcement will be the Research Project
Grant (R01), Research Program Project (P01), Research Center Grant
(P50), and First Independent Research Support and Transition (FIRST)
Award (R29).  Prospective applicants are encouraged to communicate with
the NINDS staff contact listed under INQUIRIES regarding the
appropriate funding mechanism.  Both basic science and clinical
investigations are encouraged to address relevant research issues.
 
RESEARCH OBJECTIVES
 
Background
 
Survivors of paralytic poliomyelitis have begun to suffer renewed
neurological and neuromuscular symptoms decades after maximum recovery
from the acute disease.  Symptoms include a form of progressive
muscular atrophy that involves new muscle weakness affecting certain
muscle groups, pain, fatigue, and decreased physical endurance.
Individuals who have fully recovered from the initial episode and those
who still have residual effects are at risk.  A number of terms have
been proposed to describe these late effects including post-polio
syndrome, post-polio motor neuron disease, and post-polio muscular
atrophy.
 
Estimates of the number of survivors of paralytic poliomyelitis in the
United States vary widely, from about 250,000 to over 1 million.  A
1984 epidemiological study performed by the Mayo clinic found that 25
percent of survivors had renewed symptoms, but a later follow-up of a
sample of the original respondents showed that 66 percent were
experiencing new weakness.
 
Pathologic mechanisms involved in the post-polio syndrome are not
understood, and there is evidence supporting several etiological
theories.  Changes in the motor neuron have been studied extensively.
After recovery from acute polio, axons of surviving motor neurons
sprout to reinnervate muscles whose original motor neuron did not
survive.  It is hypothesized that this process is ongoing for several
years, after which the capacity of the motor neuron to reinnervate
additional muscles is reached and the nerve terminals begin to
degenerate.
 
A recent report of IgM antibodies to the polio virus in some patients
with recurring weakness suggests that late effects of the long dormant
polio virus may play a role.  Other hypotheses that have been studied
include neuromuscular changes caused by premature aging in polio
patients, an immunological mechanism, and spinal cord changes affecting
motor neurons.
 
Research Goals and Scope
 
Multidisciplinary or collaborative studies of the post-polio syndrome
are encouraged.  Examples are given below, but applications are not
limited to these areas of research:
 
o   Epidemiological studies to determine the prevalence of post-polio
syndrome and to develop standardized diagnostic criteria.
 
o   Pathogenetic studies emphasizing the relative stability of
reinnervation following infection with the polio virus, terminal
sprouting, and growth factors.
 
o   Animal models to study the pathogenesis of the original insult,
reinnervation, possible reappearance of symptoms, and restoration of
function.
 
o   Use of new molecular biological techniques such as cloned polio
cDNAs and the polymerase chain reaction (PCR) to detect the polio
virus.
 
o   Development of strategies of immunotherapy if it is determined that
an autoimmune mechanism is involved.
 
o   Development of therapeutic strategies to improve or restore
neuromuscular function.
 
STUDY POPULATIONS
 
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS
 
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to include
minorities and women in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder or
condition under study; special emphasis must be placed on the need for
inclusion of minorities and women in studies of diseases, disorders and
conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale must be provided.
 
The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study.  This information must be included in the form PHS 398 in
Section 2, A-D of the research plan AND summarized in Section 2, E,
Human Subjects.  Applicants/offerors are urged to assess carefully the
feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).  The rationale
for studies on single minority population groups must be provided.
 
For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and preventive strategies), diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.
 
The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.
 
For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.
 
If the required information is not contained within the application,
the review will be deferred until the information is provided.
 
Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed and the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.
 
All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.
 
APPLICATION PROCEDURES
 
Applications must be submitted on the grant application form PHS 398
according to instructions contained in the application kit.
Applications submitted after May 1, 1992, are to use the 9/91 revision
of the form PHS 398.  Application kits are available from most
institutional business offices and may be obtained from the Office of
Grants Inquiries, Division of Research Grants, Westwood Building, Room
449, National Institutes of Health, Bethesda, MD  20892, telephone
301-496-7441.
 
Check "yes" in item two on the face page of the application and type
"Post-Polio Syndrome, PA-92-40."
 
Applicants for the P01 or P50 must use the application format as
described in the NINDS pamphlet, "Application Guidelines: Program
Project and Clinical Research Center Grants," that may be obtained from
the contacts listed under INQUIRIES.
 
Deadlines for the receipt of applications are February 1, June 1, and
October 1.  The completed original application and six legible copies
must be sent or delivered to:
 
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892
 
REVIEW PROCEDURES
 
Applications will be assigned on the basis of established Public Health
Service referral guidelines.  Applications will be judged on scientific
merit and program relevance in accordance with NIH policy and
procedures involving peer review.  An initial review will be made by an
appropriate study section of the Division of Research Grants for
research grants and FIRST awards and by an appropriate institute
committee for program projects and centers.  A second level of review
will be made by an appropriate national advisory council.
 
AWARD CRITERIA
 
Applications will compete for available funds with all other approved
applications.  The following will be used in making funding decisions:
 
o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the announcement
 
INQUIRIES
 
For further information regarding this announcement, potential
applicants may write or call:
 
Paul L. Nichols, Ph.D.
Developmental Neurology Branch
Division of Developmental, Convulsive, and Neuromuscular Disorders
National Institute of Neurological Disorders and Stroke
Federal Building, Room 8C08
Bethesda, MD  20892
Telephone:  (301) 496-5821
 
For fiscal and administrative inquires regarding this announcement,
potential applicants may write or call:
 
Dwight H. Mowery, Jr.
Grants Management Specialist
Grants Management Branch
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
Bethesda, MD  20892
Telephone:  (301) 496-9231
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic Assistance
No. 93.853 Clinical Research Related Neurological Disorders and 93.854
Biological Basis Research in the Neurosciences.  Awards are made under
authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-150, 42 USC 241 and
285) and administered under PHS grants policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
 
$$P3 END ************************************************************
 
                               ERRATUM
 
$$E1 BEGIN P3 19920117 APPEND PA-92-32 BOTH ****************************
 
MINORITY SCHOOL FACULTY DEVELOPMENT AWARD
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
PA NUMBER:  PA-92-32
 
P.T. 14, FF; K.W. 0715035, 0710030
 
National Cancer Institute
 
Application Receipt Dates:  February 1, 1992, June 1, 1992, October 1,
1992
 
This program announcement, Minority School Faculty Development Award,
was published in the NIH Guide for Grants and Contracts on January 17,
1992, Vol. 21, No. 2.  This erratum corrects the information in the
MECHANISM OF SUPPORT section.  The correct funding mechanism for this
program is the Minority School Faculty Development Award (K14).
 
INQUIRIES
 
Direct inquiries concerning this program to:
 
Dr. Lemuel Evans
Division of Extramural Activities
Comprehensive Minority Biomedical Program
National Cancer Institute
Building 31, Room 10A04
Bethesda, MD  20892
Telephone:  (301) 496-7344
FAX:  (301) 402-0062
 
$$E1 END ************************************************************
 
$$E2 BEGIN R5 19920124 APPEND RFA NR-92-02 SHORT ***********************
 
EXPLORATORY CENTERS FOR BIOBEHAVIOR SYMPTOM MANAGEMENT
 
NIH GUIDE, Volume 21, Number 5, February 7, 1992
 
RFA:  NR-92-02
 
P.T. 04; K.W. 0715020, 0785130, 0404000, 0785035, 0710030
 
National Center for Nursing Research
 
Letter of Intent Receipt Date:  March 31, 1992
Application Receipt Date:  May 7, 1992
 
The notice of availability for this Request for Applications was
published in the NIH Guide for Grants and Contracts on January 24,
1992, Vol. 21, No. 3, Part II of II.  The section, RESEARCH OBJECTIVES,
contained an error in the third paragraph.  This entire paragraph,
shown below, indicates that "symptoms specific to psychiatric disorders
are not included in the scope of this RFA."
 
The theoretical basis for the planned feasibility/pilot studies must be
clearly explicated for the behavioral, psychosocial, and physiological
strategies described in the exploratory center grant application.  The
symptom(s) for exploration is to be selected by the applicants and may
include, but is not limited to, the high priority symptoms of pain,
fatigue, dyspnea, nausea, vomiting, cognitive impairment, altered sleep
or rest patterns, and depression or anxiety secondary to a physical
illness.  However, symptoms specific to psychiatric disorders are not
included in the scope of this RFA.  One or more symptoms may be
selected by each applicants depending on the scientific expertise
available at the applicant institution or clinical setting and the
theoretical basis chosen to explicate the research.  An
interdisciplinary approach must be utilized.  Although
feasibility/pilot studies addressing only pharmacological interventions
are not acceptable, the inclusion of pharmacological strategies in
combination with non pharmacologic strategies is appropriate for a
multimodal management approach.
 
$$E2 END ************************************************************
 
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
 
5333 Westbard Avenue
Bethesda, MD  20816